Congress and the Trump administration are riled up about pharma prices and promising to drive them down, but a new U.S. government report shows growth in retail drug spending screeched to a halt in 2017.
The data, released by the Centers for Medicare & Medicaid Services Thursday, show growth in spending on pharmacy-dispensed drugs slowed to 0.4% last year, down sharply from 2.3% in 2016—and even more sharply from the increases in 2015 and 2014, CMS reported. Drug costs for those years grew 8.9% and 12.4%, respectively.
Why the slowdown? For one thing, drugmakers pushed through lower price hikes, CMS said. Prescription growth also slowed, while more patients started on generics and generic prices dropped, the agency said.
The new CMS data hit as drug prices continue to occupy center stage in Washington. After years of scrutiny on pharma’s pricing practices—and annual increases in prices and costs—Congress and the Trump administration have made the issue a priority. The FDA is approving generics at a record pace and prioritizing applications for drugs with little to no competition. The administration is working to force drugmakers to include prices in TV ads and lower certain U.S. prices closer to international levels, among a slew of other proposals.
Meanwhile, uncomfortable in the spotlight, many drugmakers have pumped the brakes on price hikes. Pfizer, for instance, raised prices this summer but backpedaled—at least temporarily—after the president slammed the company on Twitter. Trump tweeted that Pfizer “should be ashamed” about the move, and the company decided to defer price hikes. It now appears ready to raise them again in early 2019.
During the Pfizer controversy, other large drugmakers such as Novartis and Roche said they wouldn’t raise prices again in 2018.
By Eric Sagonowsky
Source: Fierce Pharma
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.